Skip to content
OpenCapital
Get started

Prime Medicine PRME Cash & Equivalents

Cash & Equivalents at other companies

Eli Lilly logo
Eli LillyLLY
$5.28B+70.8%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$5.5B+17.5%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$134.7M+6.2%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$423.31M+80.0%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$288.29M-45.4%
Regenxbio logo
RegenxbioRGNX
$15.23M-88.3%

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%—

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's cash & equivalents?
Prime Medicine (PRME) reported cash & equivalents of $77.8M in Q1 2026.
How has Prime Medicine's cash & equivalents changed year-over-year?
Prime Medicine's cash & equivalents decreased by 26.6% year-over-year, from $105.94M to $77.8M.
What is the long-term trend for Prime Medicine's cash & equivalents?
Over 5 years (2020 to 2025), Prime Medicine's cash & equivalents has grown at a 15.7% compound annual growth rate (CAGR), from $36.98M to $76.72M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.